Life Biosciences

Emerging

Closed $80M Series D (Apr 2026). FDA-cleared IND for ER-100 in optic neuropathies (Jan 2026). Phase 1 enrolling. Co-founded by Harvard's David Sinclair.

Longevity / Epigenetic Reprogramming
Visit Website
Updated April 2026

Company Overview

About Life Biosciences

Life Biosciences is running the first FDA-cleared human trial of partial epigenetic reprogramming, using gene therapy to reverse vision loss caused by aging. Co-founded by Harvard aging biologist David Sinclair — whose research showed that aged retinal cells could be restored to youthful function by expressing Yamanaka factors — Life Biosciences received FDA clearance for its IND (Investigational New Drug) for ER-100 in optic neuropathies in January 2026 and closed an $80 million Series D in April 2026.

Business Model & Competitive Advantage

The optic neuropathy indication is a smart clinical strategy: the eye is an immune-privileged site that allows targeted gene therapy delivery with minimal systemic risk, enabling safety data to be collected in a setting where the target tissue and disease are well-characterized. Positive safety and efficacy data in the eye would establish proof-of-concept for epigenetic reprogramming in vivo, enabling the approach to be extended to systemic aging across other tissues.

Competitive Landscape 2025–2026

The $80 million Series D provides runway through trial completion and positions Life Biosciences as the first company to generate human clinical data on whether the epigenetic clock of aging can be reversed — a question with transformative implications for medicine if the answer is yes.

Revenue
$80M
Curated content • Fact-checked and verified
Loading News...
Loading Culture...

Open Positions

Reddit Discussions

Loading Competitive Intelligence...

Key Differentiators

Emerging Innovator

Life Biosciences is an emerging player bringing innovative solutions to the BioTech market.

Frequently Asked Questions

Not So Random Others

a2z Radiology AI

Enterprise AI
Ai PoweredB2bEnterpriseHealthtechSaasStartup

a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea

Adept AI

AI Infra
Ai PoweredAutomationB2bEnterpriseInfrastructurePlatformStartupSaas

Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec

Duckie

Infrastructure
Ai PoweredAutomationB2bInfrastructurePlatformCloud NativeSaas

Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit

Plenty

AgTech & Precision Agriculture Technology
AgricultureAi PoweredHardwareIotPlatformSaasScaleupStartupB2b

Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r

Oura

Consumer Tech
B2cHardwareHealthtechIot

Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi

Nira Energy

Climate & Energy
B2bEnergy

Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify

Compare Life Biosciences with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For Life Biosciences

Claim This Profile

Are you from Life Biosciences? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Life Biosciences Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Life Biosciences vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →